Dana Callow

Mr. Callow is a founder and Managing Partner of Boston Millennia Partners, a private equity investmentmanagement organization with approximately $ 750 million under management among several multi-stageprivate funds. Prior to forming Boston Millennia Partners, Mr. Callow co-founded Boston Capital Ventures in1982 and is a Partner in four of its investment partnerships. Prior to that, he worked as a Senior Consultantat Braxton Associates, an international strategic planning firm that was organized by professionals fromBoston Consulting Group and Bain & Co. His primary clients were Fortune 100 multinational companieswhere he advised senior management on strategic planning and implementing merger and acquisitionstrategies. Prior to his activity in the management consulting business, Mr. Callow worked in sales andmarketing for Tymshare, Inc. a venture funded and subsequent public company in the cloud and remotecomputing sector which was acquired by McDonnell-Douglas.

In 1986, he was the founding institutional investor in PAREXEL International Corporation, and continues asits Presiding Director and Chair of the governance committee. (Nasdaq: PRXL). From its inception and seedfunding with four employees, PAREXEL is now the third largest clinical research organization worldwidegenerating revenues in excess of $ 1.8 billion annually with approximately 15,000 employees in 70countries. Its current sales backlog exceeds $ 4.5 billion.

He is a lead investor in, or has served as, a Director of a number of other public and private companies,including ILEX Oncology, Inc. (Nasdaq: ILXO), a cancer pharmaceutical company acquired by Genzyme for$1 billion; MedAptus, Inc., a mobile computing provider of clinical, financial and administrative softwaresolutions to the medical community; and PHT Technologies, Inc., a provider of mobile and Web-basedtechnology solutions to the pharmaceutical industry focused on patient outcomes and clinical trialsmanagement. Other investment responsibilities included Glycofi Inc., (acquired by Merck, NYSE: MRK);HotJobs, Inc. (acquired by Yahoo, NasdaqGS: YHOO); iVillage, Inc. (acquired by NBC Universal, asubsidiary of General Electric, NYSE: GE); and Tektagen, Inc. (acquired by Charles River Laboratories,NYSE: CRL). Mr. Callow manages investments in CardioMems, Inc, a cardiovascular heart sensor devicefor the treatment of congestive heart failure, and Arthrosurface, Inc., a developer and manufacturer ofadvanced orthopedic devices. Mr. Callow is a past Director of Jobs for Massachusetts, a Massachusettsbased non-profit organization comprised of business and political leaders including Governors Mitt Romneyand Deval Patrick.

Dana is a Member of the National Board of Directors of the Leukemia and Lymphoma Society, a $ 300million in annual budget non-profit organization advancing the research and treatment of blood cancersworldwide and chairs its Therapeutic Acceleration Program Committee. He is a member of the Board ofTrustees and the Chairman of the Investment Committee at Tufts University and on the Board of Overseersat Tufts University Medical School. He is a member of the Advisory Board of the Amos Tuck Center forPrivate Equity and Entrepreneurship at Dartmouth College. Mr. Callow is a graduate of Tufts University andholds an MBA from the Amos Tuck School at Dartmouth College.